Jeffrey Rosen, MD
Internal Medicine · Coral Gables, FLNPI 1972555217
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (37.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi Pasteur Inc. at 38.0% of the total. Reporting peaked in 2019 at $36,748 and has fallen 80.2% since, to $7,294 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $219.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$22K
- Sanofi-aventis U.S. LLC$11K
- Siemens Medical Solutions USA, Inc.$7K
- Lilly USA, LLC$6K
- Merck$3K
- Eli Lilly$3K
- plus $6K from 19 others
Across 2,165 payments — averaging $7859.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8.3M
- AstraZeneca$2.5M
- Merck$2.2M
- Eli Lilly$790K
- Sanofi US Services Inc.$489K
- GSK$454K
- plus $2.3M from 23 others
What the payments were for
- Consulting fees$12,48322%
- Speaking & faculty fees$17,63431%
- Travel & lodging$21,40837%
- Food & beverage$5,64210%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 48 | $21,706 |
| Sanofi-aventis U.S. LLC | 4 | $10,791 |
| Siemens Medical Solutions USA, Inc. | 5 | $6,755 |
| Lilly USA, LLC | 68 | $6,396 |
| Merck | 24 | $2,672 |
| Eli Lilly | 44 | $2,564 |
| Novo Nordisk | 12 | $1,693 |
| Novo Nordisk AS | 6 | $1,602 |
| Ferring Pharmaceuticals AS | 13 | $1,032 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $700 |
| Astrazeneca UK Limited | 6 | $374 |
| Abbott | 5 | $344 |
| AbbVie | 7 | $147 |
| Medtronic | 2 | $142 |
| Pfizer | 3 | $61 |
| GSK | 3 | $47 |
| Bayer | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $23 |
| Exact Sciences | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Amgen | 1 | $16 |
| Duchesnay USA Incorporated | 1 | $13 |
| Kvk-tech, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLUZONE HIGH-DOSE$20,839
- FLUBLOK QUADRIVALENT$8,526
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$7,485
- Atellica IM 1300 Analyzer$6,755
- Ozempic$1,717
- V114$1,360
- NOCDURNA$797
- GARDASIL 9$588
- ENSITE$283
- VenaSeal$119
How this compares
$57,186 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 45 | $49,480 |
| ProliaDenosumab | 23 | $38,504 |
| OzempicSemaglutide | 34 | $36,001 |
| JardianceEmpagliflozin | 22 | $23,725 |
| TrulicityDulaglutide | 11 | $16,914 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 52 | $11,449 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 51 | $3,540 |
| Testosterone | 13 | $3,367 |
| SynthroidLevothyroxine Sodium | 23 | $2,243 |
| Atorvastatin Calcium | 199 | $1,644 |
| Levothyroxine Sodium | 89 | $1,460 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $1,222 |
| Rosuvastatin Calcium | 78 | $1,181 |
| Nebivolol Hcl | 13 | $1,070 |
| Simvastatin | 100 | $890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $6,396 | $66,39456 claims |
| AmgenProlia | $16 | $38,50423 claims |
| Novo NordiskOzempic | $1,693 | $36,00134 claims |
| GSKShingrix | $47 | $11,44952 claims |
| AbbVieSynthroid | $147 | $2,24323 claims |
| Sanofi-aventis U.S. LLCLantus | $10,791 | $1,22217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Coral Gables
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.